Xiao Haoxiang, Xie Yuqiao, Xi Kaiwen, Xie Jinyi, Liu Mingyue, Zhang Yangming, Cheng Zishuo, Wang Wenting, Guo Baolin, Wu Shengxi
Department of Neurobiology, School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
Medical School, Yan'an University, Yan'an, China.
Aging Dis. 2023 Oct 1;14(5):1583-1605. doi: 10.14336/AD.2023.0203.
Aging is a natural and complex biological process that is associated with widespread functional declines in numerous physiological processes, terminally affecting multiple organs and tissues. Fibrosis and neurodegenerative diseases (NDs) often occur with aging, imposing large burdens on public health worldwide, and there are currently no effective treatment strategies for these diseases. Mitochondrial sirtuins (SIRT3-5), which are members of the sirtuin family of NAD-dependent deacylases and ADP-ribosyltransferases, are capable of regulating mitochondrial function by modifying mitochondrial proteins that participate in the regulation of cell survival under various physiological and pathological conditions. A growing body of evidence has revealed that SIRT3-5 exert protective effects against fibrosis in multiple organs and tissues, including the heart, liver, and kidney. SIRT3-5 are also involved in multiple age-related NDs, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Furthermore, SIRT3-5 have been noted as promising targets for antifibrotic therapies and the treatment of NDs. This review systematically highlights recent advances in knowledge regarding the role of SIRT3-5 in fibrosis and NDs and discusses SIRT3-5 as therapeutic targets for NDs and fibrosis.
衰老 是一个自然而复杂的生物学过程,与众多生理过程中广泛的功能衰退相关,最终影响多个器官和组织。纤维化和神经退行性疾病(NDs)常伴随衰老出现,给全球公共卫生带来沉重负担,目前这些疾病尚无有效的治疗策略。线粒体沉默调节蛋白(SIRT3 - 5)是依赖烟酰胺腺嘌呤二核苷酸(NAD)的脱酰基酶和ADP - 核糖基转移酶沉默调节蛋白家族的成员,能够通过修饰参与各种生理和病理条件下细胞存活调节的线粒体蛋白来调节线粒体功能。越来越多的证据表明,SIRT3 - 5对包括心脏、肝脏和肾脏在内的多个器官和组织中的纤维化具有保护作用。SIRT3 - 5还参与多种与年龄相关的神经退行性疾病,包括阿尔茨海默病、帕金森病和亨廷顿病。此外,SIRT3 - 5已被视为抗纤维化治疗和神经退行性疾病治疗的有前景的靶点。本综述系统地强调了关于SIRT3 - 5在纤维化和神经退行性疾病中作用的最新知识进展,并讨论了SIRT3 - 5作为神经退行性疾病和纤维化治疗靶点的情况。